Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Health Care Laggard

Regeneron Pharmaceuticals ( REGN) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.3%. By the end of trading, Regeneron Pharmaceuticals fell $4.46 (-1.9%) to $229.02 on light volume. Throughout the day, 678,938 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1,258,800 shares. The stock ranged in price between $225.78-$235.99 after having opened the day at $234.81 as compared to the previous trading day's close of $233.48. Other companies within the Health Care sector that declined today were: Biota Pharmaceuticals ( BOTA), down 70.1%, Mast Therapeutics ( MSTX), down 37.2%, Redhill Biopharma ( RDHL), down 20.0% and Natus Medical ( BABY), down 13.2%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $22.3 billion and is part of the drugs industry. Shares are up 36.5% year to date as of the close of trading on Friday. Currently there are 11 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Biostar Pharmaceuticals ( BSPM), up 20.1%, Alcobra ( ADHD), up 15.5%, Epizyme ( EPZM), up 14.3% and Inovio Pharmaceuticals ( INO), up 11.8% , were all gainers within the health care sector with Baxter International ( BAX) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)